Another hiccup for GW Pharma's seizure drug rival, as Zogenix discloses FDA review delay
Zogenix has had a troubling 2020 so far. Earlier this month, its experimental seizure drug met the main goal in a pivotal study in patients with Lennox-Gastaut Syndrome, but the company saw its shares plummet after the magnitude of the therapy’s effect fell short of Wall Street expectations. On Thursday, the drug developer said that the FDA had extended the review of the drug in patients with Dravet syndrome by three months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.